Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion

Secukinumab, an interleukin (IL)-17A antagonist, was associated with disease exacerbations in Crohn’s disease, and de novo cases of inflammatory bowel disease (IBD) have been reported in studies of rheumatoid diseases. However, there has been no detailed report demonstrating the linkage between secu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:ACG Case Rep J
Autori principali: Wang, Jingzhou, Bhatia, Arvin, Krugliak Cleveland, Noa, Gupta, Nina, Dalal, Sushila, Rubin, David T., Sakuraba, Atsushi
Natura: Artigo
Lingua:Inglês
Pubblicazione: American College of Gastroenterology 2018
Soggetti:
Case Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6072803/
https://ncbi.nlm.nih.gov/pubmed/30105273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14309/crj.2018.56
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi